Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2017, Article ID 4653512, 17 pages
https://doi.org/10.1155/2017/4653512
Review Article

Recent Pathophysiological Aspects of Peyronie’s Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment—Literature Review

1Regina Apostolorum Hospital, Andrology Center, Albano Laziale, Rome, Italy
2Castelfidardo Medical Team, Peyronie’s Disease Care Center, Rome, Italy
3Italian League against Cancer, Department of Urologic Oncology, Section of Avellino, Avellino, Italy
4Faculty of Pharmacy, University of Rome “La Sapienza”, Rome, Italy
5Department of Urology, Andrology Center, San Matteo Hospital, Pavia, Italy

Correspondence should be addressed to Gianni Paulis; ti.orebil@gsiluap

Received 15 March 2017; Accepted 30 May 2017; Published 4 July 2017

Academic Editor: Matthew Rutman

Copyright © 2017 Gianni Paulis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. Schwarzer, F. Sommer, T. Klotz, M. Braun, B. Reifenrath, and U. Engelmann, “The prevalence of Peyronie's disease: results of a large survey,” BJU International, vol. 88, no. 7, pp. 727–730, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. D. B. DiBenedetti, D. Nguyen, L. Zografos, R. Ziemiecki, and X. Zhou, “A Population-based study of peyronie's disease: prevalence and treatment patterns in the United States,” Advances in Urology, vol. 2011, Article ID 282503, 9 pages, 2011. View at Publisher · View at Google Scholar
  3. A. P. Saboeiro, J. J. Pokorny, S. I. Shehadi, K. S. Virgo, and F. E. Johnson, “Racial distribution of dupuytren’s disease in department of veterans affairs patients,” Plastic & Reconstructive Surgery, vol. 106, no. 1, pp. 71–75, 2000. View at Publisher · View at Google Scholar
  4. J. P. Jarow and F. C. Lowe, “Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction,” The Journal of Urology, vol. 158, no. 4, pp. 1388–1390, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. C. J. Devine Jr., K. D. Somers, G. H. Jordan, and S. M. Schlossberg, “Proposal: trauma as the cause of the Peyronie's lesion,” Journal of Urology, vol. 157, no. 1, pp. 285–290, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. A. I. El-Sakka, E. Salabas, M. Dinçer, and A. Kadioglu, “The pathophysiology of Peyronie's disease,” Arab Journal of Urology, vol. 11, no. 3, pp. 272–277, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Rompel, G. Mueller-Eckhardt, I. Schroeder-Printzen, and W. Weidner, “HLA antigens in Peyronie's disease,” Urologia Internationalis, vol. 52, no. 1, pp. 34–37, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. A. S. Herati and A. W. Pastuszak, “The Genetic Basis of Peyronie Disease: A Review,” Sexual Medicine Reviews, vol. 4, no. 1, pp. 85–94, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. G. H. Dolmans, P. M. Werker, I. J. de Jong, R. J. Nijman, C. Wijmenga, and R. A. Ophoff, “WNT2 Locus Is Involved in Genetic Susceptibility of Peyronie's Disease,” Journal of Sexual Medicine, vol. 9, no. 5, pp. 1430–1434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Byström and C. Rubio, “Induratio penis plastica (peyronie's disease): Clinical features and etiology,” Scandinavian Journal of Urology and Nephrology, vol. 10, no. 1, pp. 12–20, 1976. View at Publisher · View at Google Scholar · View at Scopus
  11. K. D. Somers, E. N. Sismour, G. L. Wright Jr., C. J. Devine Jr., D. A. Gilbert, and C. E. Horton, “Isolation and characterization of collagen in Peyronie's disease,” Journal of Urology, vol. 141, no. 3 I, pp. 629–631, 1989. View at Google Scholar · View at Scopus
  12. J. P. Pryor and D. J. Ralph, “Clinical presentations of Peyronie's disease,” International Journal of Impotence Research, vol. 14, no. 5, pp. 414–417, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. C. J. Nelson, C. Diblasio, M. Kendirci, W. Hellstrom, P. Guhring, and J. P. Mulhall, “The chronology of depression and distress in men with peyronie's disease,” Journal of Sexual Medicine, vol. 5, no. 8, pp. 1985–1990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Weidner, I. Schroeder-Printzen, W.-H. Weiske, and R. Vosshenrich, “Sexual dysfunction in Peyronie's disease: An analysis of 222 patients without previous local plaque therapy,” Journal of Urology, vol. 157, no. 1, pp. 325–328, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Akkus, S. Carrier, K. Baba et al., “Structural alterations in the tunica albuginea of the penis: Impact of Peyronie's disease, ageing and impotence,” British Journal of Urology, vol. 79, no. 1, pp. 47–53, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. LA. Levine and S. Larsen, “Diagnosis and management of peyronie disease,” in Campbell-Walsh Urology, A. J. Wein, L. R. Kavoussi, A. W. Partin, and C. A. Peters, Eds., vol. 1, Chap 31, pp. 722–748, Elsevier Saunders, Philadelphia, Pa, USA, 11th edition, 2015. View at Google Scholar
  17. G. Garaffa, L. W. Trost, E. C. Serefoglu, D. Ralph, and W. J. G. Hellstrom, “Understanding the course of Peyronie's disease,” International Journal of Clinical Practice, vol. 67, no. 8, pp. 781–788, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Brock, G.-L. Hsu, L. Nunes, B. von Heyden, and T. F. Lue, “The anatomy of the tunica albuginea in the normal penis and Peyronie's disease,” Journal of Urology, vol. 157, no. 1, pp. 276–281, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. G.-. Hsu, G. Brock, B. Von Heyden, L. Nunes, T. F. Lue, and E. A. Tanagho, “The distribution of elastic fibrous elements within the human penis,” British Journal of Urology, vol. 73, no. 5, pp. 566–571, 1994. View at Publisher · View at Google Scholar · View at Scopus
  20. K. D. Somers and D. M. Dawson, “Fibrin deposition in Peyronie's disease plaque,” Journal of Urology, vol. 157, no. 1, pp. 311–315, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Gentile, A. Modesti, G. La Pera et al., “Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive dysfunction,” Journal of Andrology, vol. 17, no. 2, pp. 96–103, 1996. View at Google Scholar · View at Scopus
  22. N. F. Gonzalez-Cadavid, T. R. Magee, M. Ferrini, A. Qian, D. Vernet, and J. Rajfer, “Gene expression in Peyronie's disease,” International Journal of Impotence Research, vol. 14, no. 5, pp. 361–374, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. K. Agarwal, “Integrins and cadherins as therapeutic targets in fibrosis,” Frontiers in Pharmacology, vol. 5, article 131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Wahl, G. L. Costa, D. E. Mizel, J. B. Allen, U. Skaleric, and D. F. Mangan, “Role of transforming growth factor beta in the pathophysiology of chronic inflammation.,” Journal of Periodontology, vol. 64, no. 5, pp. 450–455, 1993. View at Google Scholar · View at Scopus
  25. J.-K. Ryu, W.-J. Kim, M.-J. Choi et al., “Inhibition of histone deacetylase 2 mitigates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque,” Asian Journal of Andrology, vol. 15, no. 5, pp. 640–645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. B. Moreland and A. Nehra, “Pathophysiology of Peyronie’s disease,” International Journal of Impotence Research, vol. 14, no. 5, pp. 406–410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Del Carlo, A. A. Cole, and L. A. Levine, “Differential Calcium Independent Regulation of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases by Interleukin-1β and Transforming Growth Factor-β in Peyronie's Plaque Fibroblasts,” Journal of Urology, vol. 179, no. 6, pp. 2447–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. D. R. Edwards, K. J. Leco, P. P. Beaudry, P. W. Atadja, C. Veillette, and K. T. Riabowol, “Differential effects of transforming growth factor-β1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts,” Experimental Gerontology, vol. 31, no. 1-2, pp. 207–223, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. JP. Mulhall, “The clinical implications of basic science research in Peyronies disease, a guide to clinical management,” in Current clinical urology: Peyronie’s disease, LA. Levine, Ed., pp. 39–58, Humana Press, Totowa, NJ, USA, 2007. View at Google Scholar
  30. S. C. Sikka and W. J. G. Hellstrom, “Role of oxidative stress and antioxidants in Peyronie's disease,” International Journal of Impotence Research, vol. 14, no. 5, pp. 353–360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Sakurai, N. Shigemori, K. Hasegawa, and T. Sugita, “TGF-β-activated kinase 1 stimulates NF-κB activation by an NF-κB-inducing kinase-independent mechanism,” Biochemical and Biophysical Research Communications, vol. 243, no. 2, pp. 545–549, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Vernet, G. Nolazco, L. Cantini et al., “Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease,” Biology of Reproduction, vol. 73, no. 6, pp. 1199–1210, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Lambert, E. Dassé, B. Haye, and E. Petitfrère, “TIMPs as multifacial proteins,” Critical Reviews in Oncology/Hematology, vol. 49, no. 3, pp. 187–198, 2004. View at Publisher · View at Google Scholar
  34. T. J. Bivalacqual, H. C. Champion, and W. J. G. Hellstrom, “Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease,” International Journal of Impotence Research, vol. 14, no. 5, pp. 345–352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Paulis and T. Brancato, “Inflammatory mechanisms and oxidative stress in Peyronie's disease: Therapeutic "rationale" and related emerging treatment strategies,” Inflammation and Allergy - Drug Targets, vol. 11, no. 1, pp. 48–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Huleihel, A. Douvdevani, S. Segal, and R. N. Apte, “Regulation of interleukin 1 generation in immune‐activated fibroblasts,” European Journal of Immunology, vol. 20, no. 4, pp. 731–738, 1990. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Sasaki, T. Hattori, T. Fujisawa, K. Takahashi, H. Inoue, and M. Takigawa, “Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes,” Journal of Biochemistry, vol. 123, no. 3, pp. 431–439, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. R. J. Van't Hof, K. J. Armour, L. M. Smith et al., “Requirement of the inducible nitric oxide synthase pathway for IL-1- induced osteoclastic bone resorption,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 7993–7998, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. H. H. Davila, T. R. Magee, D. Vernet, J. Rajfer, and N. F. Gonzalez-Cadavid, “Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease,” Biology of Reproduction, vol. 71, no. 5, pp. 1568–1577, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. H. H. Davila, T. R. Magee, F. I. Zuniga, J. Rajfer, and N. F. Gonzalez-Cadavid, “Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque,” Urology, vol. 65, no. 4, pp. 645–648, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Sasaki, M. Kashima, T. Ito et al., “Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1β and TNF-α,” Mediators of Inflammation, vol. 9, no. 3-4, pp. 155–160, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. M. M. Chaturvedi, M. Higuchi, and B. B. Aggarwal, “Effect of tumor necrosis factors, interferons, interleukins, and growth factors on the activation of NF-κB: Evidence for lack of correlation with cell proliferation,” Lymphokine and Cytokine Research, vol. 13, no. 5, pp. 309–313, 1994. View at Google Scholar · View at Scopus
  43. R.-M. Liu, “Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis,” Antioxidants and Redox Signaling, vol. 10, no. 2, pp. 303–319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Agarwal, K. C. Nandipati, R. K. Sharma, C. D. Zippe, and R. Raina, “Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction,” Journal of Andrology, vol. 27, no. 3, pp. 335–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Nava and S. Llorens, “The paracrine control of vascular motion. A historical perspective,” Pharmacological Research, vol. 113, pp. 125–145, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. R. M. J. Palmer, D. S. Ashton, and S. Moncada, “Vascular endothelial cells synthesize nitric oxide from L-arginine,” Nature, vol. 333, no. 6174, pp. 664–666, 1988. View at Publisher · View at Google Scholar · View at Scopus
  47. W. W. Scott and P. L. Scardino, “A new concept in the treatment of peyronie's disease,” Southern Medical Journal, vol. 41, no. 2, pp. 173–177, 1948. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Cachia, J. El Benna, E. Pedruzzi, B. Descomps, M.-A. Gougerot-Pocidalo, and C.-L. Leger, “α-Tocopherol inhibits the respiratory burst in human monocytes: Attenuation of p47(phox) membrane translocation and phosphorylation,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32801–32805, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Tasanarong, S. Kongkham, S. Duangchana, S. Thitiarchakul, and S. Eiam-Ong, “Vitamin E ameliorates renal fibrosis by inhibition of TGF-beta/Smad2/3 signaling pathway in UUO mice,” Journal of the Medical Association of Thailand, vol. 94, Supplement 7:S1-9, 2011. View at Google Scholar · View at Scopus
  50. A. L. Haas, D. Boscoboinik, D. S. Mojon, M. Böhnke, and A. Azzi, “Vitamin E inhibits proliferation of human Tenon's capsule fibroblasts in vitro,” Ophthalmic Research, vol. 28, no. 3, pp. 171–175, 1996. View at Publisher · View at Google Scholar · View at Scopus
  51. J. P. Godbout, B. M. Berg, C. Krzyszton, and R. W. Johnson, “α-Tocopherol attenuates NFκB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide- induced sickness behavior,” Journal of Neuroimmunology, vol. 169, no. 1-2, pp. 97–105, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. Q. Jiang, X. Yin, M. A. Lil, M. L. Danielson, H. Freiser, and J. Huang, “Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 51, pp. 20464–20469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Fazzio, D. Marilley, and A. Azzi, “The effect of α-Tocopherol and β-tocopherol on proliferation, protein kinase C activity and gene expression in different cell lines.,” IUBMB Life, vol. 41, no. 1, pp. 93–101, 1997. View at Publisher · View at Google Scholar
  54. E. Kakishita, A. Suehiro, Y. Oura, and K. Nagai, “Inhibitory effect of vitamin E (α -tocopherol) on spontaneous platelet aggregation in whole blood,” Thrombosis Research, vol. 60, no. 6, pp. 489–499, 1990. View at Publisher · View at Google Scholar · View at Scopus
  55. J. J. Hu, G. C. Roush, M. Berwick et al., “Effects of dietary supplementation of alpha-tocopherol on plasma glutathione and DNA repair activities,” Cancer Epidemiol Biomarkers Prev, vol. 5, no. 4, pp. 263–270, 1996. View at Google Scholar
  56. P. L. Scardino and W. W. Scott, “THE use of tocopherols in the treatment of peyronie's disease,” Annals of the New York Academy of Sciences, vol. 52, no. 3, pp. 390–396, 1949. View at Publisher · View at Google Scholar · View at Scopus
  57. C. L. Steinberg, “Tocopherols in treatment of primary fibrositis; including Dupuytren's contracture, periarthritis of the shoulders, and Peyronie's disease,” A.M.A. Archives of Surgery, vol. 63, no. 6, p. 824, 1951. View at Publisher · View at Google Scholar
  58. J. P. Pryor and C. R. Farell, “Controlled clinical trial of vitamin E in Peyronies disease,” Prog Reprod Biol Med, vol. 9, pp. 41–45, 1983. View at Google Scholar
  59. M. R. Safarinejad, S. Y. Hosseini, and A. A. Kolahi, “Comparison of Vitamin E and Propionyl-L-Carnitine, Separately or in Combination, in Patients With Early Chronic Peyronie's Disease: A Double-Blind, Placebo Controlled, Randomized Study,” Journal of Urology, vol. 178, no. 4, pp. 1398–1403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. A. A. Halal, P. Geavlete, and E. Ceban, “Pharmacological therapy in patients diagnosed with Peyronie's disease.,” Journal of medicine and life, vol. 5, no. 2, pp. 192–195, 2012. View at Google Scholar · View at Scopus
  61. V. Favilla, G. I. Russo, and S. Privitera, “Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study,” Andrologia, vol. 46, no. 8, pp. 936–942, 2014. View at Publisher · View at Google Scholar
  62. G. Paulis, T. Brancato, R. D'Ascenzo et al., “Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases.,” Andrology, vol. 1, no. 1, pp. 120–128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. F. M. Vaz and R. J. A. Wanders, “Carnitine biosynthesis in mammals,” Biochemical Journal, vol. 361, no. 3, pp. 417–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. I. Gülçin, “Antioxidant and antiradical activities of L-carnitine,” Life Sciences, vol. 78, no. 8, pp. 803–811, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Ge, Y. Cui, F. Liu, J. Luan, X. Zhou, and J. Han, “L-carnitine affects osteoblast differentiation in NIH3T3 fibroblasts by the IGF-1/PI3K/Akt signalling pathway,” BioScience Trends, vol. 9, no. 1, pp. 42–48, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. B.-J. Lee, J.-S. Lin, Y.-C. Lin, and P.-T. Lin, “Antiinflammatory effects of l-carnitine supplementation (1000 mg/d) in coronary artery disease patients,” Nutrition, vol. 31, no. 3, pp. 475–479, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Koc, T. Ozkan, A. Z. Karabay, A. Sunguroglu, and F. Aktan, “Effect of L-carnitine on the synthesis of nitric oxide in RAW 264·7 murine macrophage cell line,” Cell Biochemistry and Function, vol. 29, no. 8, pp. 679–685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Jiang, Z. Zhang, Y. Zhang, J. Wu, L. Yu, and S. Liu, “L-carnitine ameliorates the liver inflammatory response by regulating carnitine palmitoyltransferase I-dependent PPARγ signaling,” Molecular Medicine Reports, vol. 13, no. 2, pp. 1320–1328, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Alvarez De Sotomayor, R. Bueno, C. Pérez-Guerrero, and M. D. Herrera, “Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR,” Journal of Vascular Research, vol. 44, no. 5, pp. 354–364, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Benvenga, A. Amato, M. Calvani, and F. Trimarchi, “Effects of carnitine on thyroid hormone action,” Annals of the New York Academy of Sciences, vol. 1033, pp. 158–167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Biagiotti and G. Cavallini, “Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report,” BJU International, vol. 88, no. 1, pp. 63–67, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Cavallini, G. Biagiotti, A. Koverech, and G. Vitali, “Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease,” BJU International, vol. 89, no. 9, pp. 895–900, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. J. P. De La Cruz, M. M. Romero, P. Sanchez, and F. Sanchez de la Cuesta, “Antiplatelet effect of pentoxifylline in human whole blood,” General Pharmacology, vol. 24, no. 3, pp. 605–609, 1993. View at Publisher · View at Google Scholar · View at Scopus
  74. T. W. Costantini, J. Deree, C. Y. Peterson et al., “Pentoxifylline modulates p47phox activation and downregulates neutrophil oxidative burst through PKA-dependent and -independent mechanisms,” Immunopharmacology and Immunotoxicology, vol. 32, no. 1, pp. 82–91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. V. R. Sunil, K. N. Vayas, J. A. Cervelli et al., “Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation,” Experimental and Molecular Pathology, vol. 97, no. 1, pp. 89–98, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. J. P. Freitas and P. M. Filipe, “Pentoxifylline - A hydroxyl radical scavenger,” Biological Trace Element Research, vol. 47, no. 1-3, pp. 307–311, 1995. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Lin, A. W. Shindel, L. Banie et al., “Pentoxifylline attenuates transforming growth factor-β1-stimulated elastogenesis in human Tunica albuginea-derived fibroblasts part 2: Interference in a TGF-β1/smad-dependent mechanism and downregulation of AAT1,” Journal of Sexual Medicine, vol. 7, no. 5, pp. 1787–1797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. A. W. Shindel, G. Lin, H. Ning et al., “Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix,” The Journal of Sexual Medicine, vol. 7, no. 6, pp. 2077–2085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. Q. Ji, L. Zhang, H. Jia, and J. Xu, “Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines,” Annals of Clinical & Laboratory Science, vol. 4, pp. 427–436, 2004. View at Google Scholar
  80. R. A. Isbrucker and T. C. Peterson, “Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts,” Toxicology and Applied Pharmacology, vol. 149, no. 1, pp. 120–126, 1998. View at Publisher · View at Google Scholar · View at Scopus
  81. J.-M. Anaya and L. R. Espinoza, “Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases,” Journal of Rheumatology, vol. 22, no. 4, pp. 595–599, 1995. View at Google Scholar · View at Scopus
  82. E. G. A. Valente, D. Vernet, M. G. Ferrini, A. Qian, J. Rajfer, and N. F. Gonzalez-Cadavid, “L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures,” Nitric Oxide - Biology and Chemistry, vol. 9, no. 4, pp. 229–244, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. W. O. Brant, R. C. Dean, and T. F. Lue, “Treatment of Peyronie's disease with oral pentoxifylline,” Nature Clinical Practice Urology, vol. 3, no. 2, pp. 111–115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. J. F. Smith, A. W. Shindel, Y.-C. Huang et al., “Pentoxifylline treatment and penile calcifications in men with Peyronie's disease,” Asian Journal of Andrology, vol. 13, no. 2, pp. 322–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. M. R. Abern, S. Larsen, and L. A. Levine, “Combination of penile traction, intralesional verapamil, and oral therapies for peyronie's disease,” Journal of Sexual Medicine, vol. 9, no. 1, pp. 288–295, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. F. Ciociola and G. M. Colpi, “Peyronie's disease: A triple oxygenant therapy,” Archivio Italiano di Urologia e Andrologia, vol. 85, no. 1, pp. 36–40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Dell'Atti and G. Ughi, “Efficacy of pentoxifylline in Peyronie's disease: clinical case of a young man,” Archivio Italiano di Urologia e Andrologia, vol. 86, no. 3, pp. 237–237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Alizadeh, F. Karimi, and M. R. Fallah, “Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline,” Global journal of health science, vol. 6, no. 7, pp. 23–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. G. Paulis, D. Barletta, P. Turchi et al., “Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie’s disease: a case-control study,” Research and Reports in Urology, vol. 8, pp. 1–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Frei, M. C. Kim, and B. N. Ames, “Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 12, pp. 4879–4883, 1990. View at Publisher · View at Google Scholar · View at Scopus
  91. H.-J. Jung, E.-H. Park, and C.-J. Lim, “Evaluation of anti-angiogenic, anti-inflammatory and antinociceptive activity of coenzyme Q10 in experimental animals,” Journal of Pharmacy and Pharmacology, vol. 61, no. 10, pp. 1391–1395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. G. López-Lluch, M. P. Barroso, S. F. Martín et al., “Role of plasma membrane coenzyme Q on the regulation of apoptosis,” BioFactors, vol. 9, no. 2-4, pp. 171–177, 1999. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Szardening-Kirchner, L. Konrad, E. W. Hauck, S. M. Haag, O. Eickelberg, and W. Weidner, “Upregulation of mRNA expression of MCP-1 by TGF-β1 in fibroblast cells from Peyronie's disease,” World Journal of Urology, vol. 27, no. 1, pp. 123–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Ebadi, S. K. Sharma, S. Wanpen, and A. Amornpan, “Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation,” Journal of Cellular and Molecular Medicine, vol. 8, no. 2, pp. 213–222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. M. R. Safarinejad, “Safety and efficacy of coenzyme Q 10 supplementation in early chronic Peyronie's disease: A double-blind, placebo-controlled randomized study,” International Journal of Impotence Research, vol. 22, no. 5, pp. 298–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. M. L. Khalil, “Biological activity of bee propolis in health and disease,” Asian Pacific Journal of Cancer Prevention, vol. 7, no. 1, pp. 22–31, 2006. View at Google Scholar
  97. C. Sun, Z. Wu, Z. Wang, and H. Zhang, “Effect of ethanol/water solvents on phenolic profiles and antioxidant properties of Beijing propolis extracts,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 595393, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. C. S. Machado, J. B. Mokochinski, T. O. de Lira et al., “Comparative study of chemical composition and biological activity of yellow, green, brown, and red Brazilian propolis,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 6057650, 11 pages, 2016. View at Publisher · View at Google Scholar
  99. S. Kumazawa, T. Hamasaka, and T. Nakayama, “Antioxidant activity of propolis of various geographic origins,” Food Chemistry, vol. 84, no. 3, pp. 329–339, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Huang, C.-P. Zhang, K. Wang, G. Li, and F.-L. Hu, “Recent advances in the chemical composition of propolis,” Molecules, vol. 19, no. 12, pp. 19610–19632, 2014. View at Publisher · View at Google Scholar
  101. M. Khalil and S. Sulaiman, “The potential role of honey and its polyphenols in preventing heart disease: a review,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 7, no. 4, pp. 315–321, 2010. View at Publisher · View at Google Scholar
  102. A. Russo, R. Longo, and A. Vanella, “Antioxidant activity of propolis: role of caffeic acid phenethyl ester and galangin,” Fitoterapia, vol. 73, supplement 1, pp. S21–S29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. X. Wang, G. Gong, W. Yang, Y. Li, M. Jiang, and L. Li, “Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model,” Environmental Toxicology and Pharmacology, vol. 36, no. 2, pp. 288–295, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. Y. C. Jung, M. E. Kim, J. H. Yoon et al., “Anti-inflammatory effects of galangin on lipopolysaccharide-activated macrophages via ERK and NF-κB pathway regulation,” Immunopharmacology and Immunotoxicology, vol. 36, no. 6, pp. 426–432, 2014. View at Publisher · View at Google Scholar
  105. D. Ribeiro, M. Freitas, S. M. Tomé, A. M. S. Silva, G. Porto, and E. Fernandes, “Modulation of human neutrophils' oxidative burst by flavonoids,” European Journal of Medicinal Chemistry, vol. 67, pp. 280–292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. A. W. Boots, G. R. M. M. Haenen, and A. Bast, “Health effects of quercetin: from antioxidant to nutraceutical,” European Journal of Pharmacology, vol. 585, no. 2-3, pp. 325–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. Y.-D. Min, C.-H. Choi, H. Bark et al., “Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-κB and p38 MAPK in HMC-1 human mast cell line,” Inflammation Research, vol. 56, no. 5, pp. 210–215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. G. M. Raso, R. Meli, G. di Carlo, M. Pacilio, and R. di Carlo, “Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1,” Life Sciences, vol. 68, no. 8, pp. 921–931, 2001. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Nakamura, M. Matsushima, Y. Hayashi et al., “Attenuation of transforming growth factor-β-stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1,” American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 5, pp. 614–620, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. L. C. Paracatu, C. M. Faria, C. Quinello et al., “Caffeic acid phenethyl ester: consequences of its hydrophobicity in the oxidative functions and cytokine release by leukocytes,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 793629, 13 pages, 2014. View at Publisher · View at Google Scholar
  111. F. Armutcu, S. Akyol, S. Ustunsoy, and F. F. Turan, “Therapeutic potential of caffeic acid phenethyl ester and its anti-inflammatory and immunomodulatory effects (Review),” Experimental and Therapeutic Medicine, vol. 9, no. 5, pp. 1582–1588, 2015. View at Publisher · View at Google Scholar · View at Scopus
  112. W.-X. Zhao, L. Wang, J.-L. Yang, L.-Z. Li, W.-M. Xu, and T. Li, “Caffeic acid phenethyl ester attenuates pro-inflammatory and fibrogenic phenotypes of LPS-stimulated hepatic stellate cells through the inhibition of NF-kB signaling,” International Journal of Molecular Medicine, vol. 33, no. 3, pp. 687–694, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. M. M. Mia and R. A. Bank, “The pro-fibrotic properties of transforming growth factor on human fibroblasts are counteracted by caffeic acid by inhibiting myofibroblast formation and collagen synthesis,” Cell and Tissue Research, vol. 363, no. 3, pp. 775–789, 2016. View at Publisher · View at Google Scholar · View at Scopus
  114. K. J. Woo, Y.-J. Jeong, H. Inoue, J.-W. Park, and T. K. Kwon, “Chrysin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression through the inhibition of nuclear factor for IL-6 (NF-IL6) DNA-binding activity,” FEBS Letters, vol. 579, no. 3, pp. 705–711, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. H. Cho, C.-W. Yun, W.-K. Park et al., “Modulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives,” Pharmacological Research, vol. 49, no. 1, pp. 37–43, 2004. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Ahad, A. A. Ganai, M. Mujeeb, and W. A. Siddiqui, “Chrysin, an anti-inflammatory molecule, abrogates renal dysfunction in type 2 diabetic rats,” Toxicology and Applied Pharmacology, vol. 279, no. 1, pp. 1–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. H.-M. Lo, M.-W. Wu, S.-L. Pan, C.-Y. Peng, P.-H. Wu, and W.-B. Wu, “Chrysin restores PDGF-induced inhibition on protein tyrosine phosphatase and reduces PDGF signaling in cultured VSMCs,” Journal of Nutritional Biochemistry, vol. 23, no. 6, pp. 667–678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. Dong, H. Huang, M. Zhao, D. Sun-Waterhouse, L. Lin, and C. Xiao, “Mechanisms underlying the xanthine oxidase inhibitory effects of dietary flavonoids galangin and pinobanksin,” Journal of Functional Foods, vol. 24, pp. 26–36, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. A. C. Santos, S. A. Uyemura, J. L. C. Lopes, J. N. Bazon, F. E. Mingatto, and C. Curti, “Effect of naturally occurring flavonoids on lipid peroxidation and membrane permeability transition in mitochondria,” Free Radical Biology and Medicine, vol. 24, no. 9, pp. 1455–1461, 1998. View at Publisher · View at Google Scholar · View at Scopus
  120. L.-T. Zhou, K.-J. Wang, L. Li, H. Li, and M. Geng, “Pinocembrin inhibits lipopolysaccharide-induced inflammatory mediators production in BV2 microglial cells through suppression of PI3K/Akt/NF-κB pathway,” European Journal of Pharmacology, vol. 761, pp. 211–216, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. K.-S. Chen, M.-D. Shi, C.-S. Chien, and Y.-W. Shih, “Pinocembrin suppresses TGF-β1-induced epithelial-mesenchymal transition and metastasis of human Y-79 retinoblastoma cells through inactivating αvβ3 integrin/FAK/p38α signaling pathway,” Cell and Bioscience, vol. 4, no. 1, article 41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Alday, D. Valencia, A. L. Carreño et al., “Apoptotic induction by pinobanksin and some of its ester derivatives from Sonoran propolis in a B-cell lymphoma cell line,” Chemico-Biological Interactions, vol. 242, pp. 35–44, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. W.-W. Jung, “Protective effect of apigenin against oxidative stress-induced damage in osteoblastic cells,” International Journal of Molecular Medicine, vol. 33, no. 5, pp. 1327–1334, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Landolfi, R. L. Mower, and M. Steiner, “Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations,” Biochemical Pharmacology, vol. 33, no. 9, pp. 1525–1530, 1984. View at Publisher · View at Google Scholar · View at Scopus
  125. L. Chen and W. Zhao, “Apigenin protects against bleomycin-induced lung fibrosis in rats,” Experimental and Therapeutic Medicine, vol. 11, no. 1, pp. 230–234, 2016. View at Publisher · View at Google Scholar · View at Scopus
  126. Lemourt O. M., Filgueiras L. E., Rodríguez B. A., González O. E., and Bordonado R., “Clinical evaluation of the use of propoleum in Peyronie's disease,” Archivos Españoles de Urología, vol. 51, no. 2, pp. 171–176, 1998. View at Google Scholar
  127. Lemourt O. M., Rodríguez B. A., Puente G. M., Vega G. C., Navarro C. M., and Pérez M. A., “Peyronie's disease and propoleum,” Archivos Espanoles de Urologia, vol. 56, no. 7, pp. 805–813, 2003. View at Google Scholar · View at Scopus
  128. Lemourt O. M., Rodríguez B. A., Bordonado R. R., González O. E., and Molina C. F., “Dose study with propoleum in Peyronie's disease,” Archivos Espanoles de Urologia, vol. 56, no. 7, pp. 814–819, 2003. View at Google Scholar · View at Scopus
  129. Lemourt O. M., Fragas V. R., Bordonado R. R., J. L. Santana, González O. E., and A. Merino, “Peyronie's disease. Evaluation of three therapeutic methodologies: Propoleum, laser and propoleum-laser,” Archivos Espanoles de Urologia, vol. 58, no. 9, pp. 931–935, 2005. View at Google Scholar · View at Scopus
  130. G. Paulis, R. D'Ascenzo, P. Nupieri et al., “Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: A study of 151 cases,” International Journal of Andrology, vol. 35, no. 4, pp. 521–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. G. Paulis, G. Cavallini, T. Brancato, and R. Alvaro, “Peironimev-plus® in the treatment of chronic inflammation of tunica albuginea (peyronie's disease). Results of a controlled study,” Inflammation and Allergy - Drug Targets, vol. 12, no. 1, pp. 61–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. G. Paulis, G. Cavallini, G. De Giorgio, S. Quattrocchi, T. Brancato, and R. Alvaro, “Long-term multimodal therapy (Verapamil associated with propolis, blueberry, vitamin E and local Diclofenac) on patients with peyronie's disease (chronic inflammation of the tunica albuginea). results of a controlled study,” Inflammation and Allergy - Drug Targets, vol. 12, no. 6, pp. 403–409, 2013. View at Publisher · View at Google Scholar · View at Scopus
  133. D. Burdulis, L. Ivanauskas, V. Dirse, S. Kazlauskas, and A. Razukas, “Study of diversity of anthocyanin composition in bilberry (Vaccinium myrtillus L.) fruits.,” Medicina (Kaunas, Lithuania), vol. 43, no. 12, pp. 971–977, 2007. View at Google Scholar · View at Scopus
  134. N. P. Seeram, “Berry fruits for cancer prevention: current status and future prospects,” Journal of Agricultural and Food Chemistry, vol. 56, no. 3, pp. 630–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Fleuriet, “The Main Phenolics of Fruit,” in Fruit Phenolics, J. J. Macheix, A. Fleuriet, and J. Billot, Eds., pp. 1–99, CRC Press, Inc, Boca Raton, Fla, USA, 1990. View at Google Scholar
  136. M. M. Rahman, T. Ichiyanagi, T. Komiyama, Y. Hatano, and T. Konishi, “Superoxide radical- and peroxynitrite-scavenging activity of anthocyanins; structure-activity relationship and their synergism,” Free Radical Research, vol. 40, no. 9, pp. 993–1002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. T. Ichiyanagi, Y. Hatano, S. Matsuo, and T. Konishi, “Simultaneous comparison of relative reactivities of twelve major anthocyanins in bilberry towards reactive nitrogen species,” Chemical and Pharmaceutical Bulletin, vol. 52, no. 11, pp. 1312–1315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Roth, M. R. Spalinger, C. Gottier et al., “Bilberry-derived anthocyanins modulate cytokine expression in the intestine of patients with ulcerative colitis,” PLoS ONE, vol. 11, no. 5, Article ID e0154817, 2016. View at Publisher · View at Google Scholar · View at Scopus
  139. D.-X. Hou, T. Yanagita, T. Uto, S. Masuzaki, and M. Fujii, “Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: Structure-activity relationship and molecular mechanisms involved,” Biochemical Pharmacology, vol. 70, no. 3, pp. 417–425, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. M. C. Lazzè, R. Pizzala, P. Perucca et al., “Anthocyanidins decrease endothelin-1 production and increase endothelial nitric oxide synthase in human endothelial cells,” Molecular Nutrition and Food Research, vol. 50, no. 1, pp. 44–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  141. N. Xia, A. Pautz, U. Wollscheid, G. Reifenberg, U. Förstermann, and H. Li, “Artichoke, cynarin and cyanidin downregulate the expression of inducible nitric oxide synthase in human coronary smooth muscle cells,” Molecules, vol. 19, no. 3, pp. 3654–3668, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. C. Artaria, R. Pace, G. Maramaldi, and G. Appendino, “Different brands of bilberry extract: a comparison of selected components,” NUTRAfoods, vol. 6, no. 4, pp. 13–18, 2007. View at Google Scholar
  143. I. Gouni-Berthold and A. Sachinidis, “Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases,” Current Pharmaceutical Design, vol. 10, no. 11, pp. 1261–1271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  144. T. J. Bivalacqua, H. C. Champion, S. Leungwattanakij et al., “Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's-like condition in the rat,” Journal of Andrology, vol. 22, no. 3, pp. 497–506, 2001. View at Google Scholar · View at Scopus
  145. M. G. Ferrini, D. Vernet, T. R. Magee et al., “Antifibrotic role of inducible nitric oxide synthase,” Nitric Oxide, vol. 6, no. 3, pp. 283–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Bentz, C. Zaouter, Q. Shi et al., “Inhibition of inducible nitric oxide synthase prevents lipid peroxidation in osteoarthritic chondrocytes,” Journal of Cellular Biochemistry, vol. 113, no. 7, pp. 2256–2267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  147. J.-P. Pelletier, D. Jovanovic, J. C. Fernandes et al., “Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase,” Arthritis and Rheumatism, vol. 41, no. 7, pp. 1275–1286, 1998. View at Publisher · View at Google Scholar · View at Scopus